Showing results (1-10 of 360) with videos related to

Sort By:
Pageof 36
JAMA Oncology|May 1, 2018
Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven OncologyJohn Marquart, Emerson Y Chen, Vinay Prasad
European Journal of Cancer (Oxford, England : 1990)|November 7, 2020
Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharingKate Rosen, Vinay Prasad, Emerson Y Chen
JAMA Internal Medicine|May 29, 2019
An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response RateEmerson Y Chen, Vikram Raghunathan, Vinay Prasad
Journal of Cancer Policy|September 26, 2022
Estimation of time cost of anti-cancer drugs approved based on comparisons to best supportive care: A cross sectional analysisVinay Prasad, Timothée Olivier, Emerson Y Chen, et al.
JAMA Internal Medicine|April 2, 2019
Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical TrialsEmerson Y Chen, Sunil K Joshi, Audrey Tran, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 8, 2020
Relationship Between Response and Dose in Published, Contemporary Phase I Oncology TrialsAntonious Hazim, Gordon Mills, Vinay Prasad, et al.
Future Science OA|September 28, 2020
Estimation of US patients with cancer who may respond to cytotoxic chemotherapyEdward B Maldonado, Scott Parsons, Emerson Y Chen, et al.
BMJ (Clinical Research Ed.)|March 9, 2018
Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational studyJeffrey Wagner, John Marquart, Julia Ruby, et al.
JCO Oncology Practice|January 7, 2021
Application of ASCO Value Framework to Treatment Advances in Hepatocellular CarcinomaEmerson Y Chen, Madeline Cook, Christopher Deig, et al.
BMC Cancer|August 4, 2021
The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009-2018Alyson Haslam, Jennifer Gill, Tyler Crain, et al.
Pageof 36